Arbutus Biopharma (ABUS) Non-Current Deferred Tax Liability (2015 - 2019)

Arbutus Biopharma (ABUS) has reported Non-Current Deferred Tax Liability for 5 consecutive years, with $12.7 million the latest figure, recorded in Q2 2019.

• Quarterly Non-Current Deferred Tax Liability fell 25.27% year-over-year to $12.7 million in Q2 2019, while the trailing twelve-month figure through Jun 2019 was $12.7 million (down 25.27% YoY) and the FY2018 annual result came in at $12.7 million, down 25.27% from the prior year.
• Non-Current Deferred Tax Liability was little changed at $12.7 million in Q2 2019 per ABUS's latest filing, from $12.7 million in the prior quarter.
• Over the last five years, Non-Current Deferred Tax Liability for ABUS reached as high as $156.0 million in Q2 2015 and fell as low as $12.7 million in Q3 2018.
• A 5-year average of $60.0 million and a median of $41.3 million in 2016 frame the typical range for Non-Current Deferred Tax Liability.
• Annual changes were most pronounced in 2016 — Non-Current Deferred Tax Liability tumbled 71.8% — and 2018, when it declined 25.27%.
• Year by year, Non-Current Deferred Tax Liability stood at $146.3 million in 2015, then slumped by 71.8% to $41.3 million in 2016, then plunged by 58.94% to $16.9 million in 2017, then dropped by 25.27% to $12.7 million in 2018, then changed by 0.0% to $12.7 million in 2019.
• According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $12.7 million, $12.7 million, and $12.7 million for Q2 2019, Q1 2019, and Q4 2018 respectively.